Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 5/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30256630 | 1.00 | CYP3A4 (0.32) | CYP3A4ALDH1A1TSHRMAPK1DPP4 | |
| SCHEMBL24148167 | 0.92 | DPP4 (0.32) | CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL30255831 | 0.92 | DPP4 (0.32) | CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL24148705 | 0.88 | DHPS (0.38) | CYP3A4ALDH1A1TSHRMAPK1ESR2 | |
| SCHEMBL30256096 | 0.86 | DPP4 (0.33) | CYP3A4ALDH1A1TSHRMAPK1DPP4 | |
| SCHEMBL24147935 | 0.86 | DPP4 (0.33) | CYP3A4ALDH1A1TSHRMAPK1DPP4 | |
| SCHEMBL30256145 | 0.85 | MTOR (0.35) | CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL24148079 | 0.85 | MTOR (0.35) | CYP3A4DPP4DPP8DPP9 | |
| SCHEMBL24147809 | 0.85 | — | — | |
| SCHEMBL30256215 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | CYP3A4 4459/4885ALDH1A1 2214/4885TSHR 3762/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | CYP3A4 4459/4885ALDH1A1 2214/4885TSHR 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.